drugset / Trial / NCT00002171

A Study of Viracept in HIV-Positive Women

NCT00002171

Phase 2 Completed Agouron Pharmaceuticals
Treatment

Summary

The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count \<= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelfinavir Other / unclassified